TY - JOUR
T1 - Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas
AU - Russo, Antonio
AU - Badalamenti, Giuseppe
AU - Pantano, Francesco
AU - Aglietta, Massimo
AU - Napolitano, Andrea
AU - Russo, Antonio
AU - Spalato Ceruso, Mariella
AU - Badalamenti, Giuseppe
AU - Vincenzi, Bruno
AU - Grignani, Giovanni
AU - Tonini, Giuseppe
AU - Santini, Daniele
AU - Santini, Daniele
PY - 2017
Y1 - 2017
N2 - Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
AB - Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
KW - Doxorubicin
KW - Geriatrics and Gerontology
KW - Hematology
KW - Olaratumab
KW - Oncology
KW - PDGFR-α
KW - Soft tissue sarcomas
KW - Doxorubicin
KW - Geriatrics and Gerontology
KW - Hematology
KW - Olaratumab
KW - Oncology
KW - PDGFR-α
KW - Soft tissue sarcomas
UR - http://hdl.handle.net/10447/246543
UR - http://www.elsevier.com/locate/critrevonc
M3 - Article
VL - 118
SP - 1
EP - 6
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -